Counted Out: How Decades of Research Neglect Left Female Sexual Satisfaction Without a Scientific Foundation

In 1998, sildenafil — marketed as Viagra — became a cultural phenomenon almost overnight. Within months of its approval by the U.S. Food and Drug Administration, the drug had redefined how medicine thought about male sexual health, generated billions in revenue, and triggered an explosion of downstream research into male sexual physiology. For men experiencing erectile dysfunction, a new era had arrived.

For women experiencing difficulty with arousal, desire, or orgasm, that era never came.

More than two decades later, the research infrastructure built around male sexual health dwarfs anything comparable for women. The data gap this has created is not merely an academic inconvenience. It has direct, measurable consequences for the clinical options available to women in gynecologists' offices and sexual medicine clinics across the United States today.

The Numbers Tell a Stark Story

Studies examining publication rates in peer-reviewed journals consistently find that research into male sexual dysfunction outnumbers research into female sexual dysfunction by ratios that researchers describe, with notable understatement, as "significant." A 2019 analysis published in the Journal of Sexual Medicine found that erectile dysfunction alone generated roughly five times more indexed research than all categories of female sexual dysfunction combined during the preceding decade.

This is not a reflection of prevalence. Conservative estimates suggest that between 40 and 50 percent of American women experience some form of sexual dysfunction at some point in their lives — figures that rival or exceed rates of erectile dysfunction among men. The disparity in research output, then, cannot be explained by patient need. It must be explained by something else.

Tracing the Institutional Roots

The origins of this imbalance are neither accidental nor mysterious. They are the product of layered institutional decisions made over generations.

For much of the twentieth century, women's sexuality was either pathologized — framed as a psychological problem requiring psychiatric intervention — or ignored entirely within mainstream medicine. The clinical framework that eventually emerged around female sexual response was built largely on male models, with women's physiology treated as a variation on a theme rather than a distinct biological system deserving its own foundational research.

This framing had practical consequences. When pharmaceutical companies began investing heavily in sexual health research during the 1990s, they did so within an existing infrastructure that had already mapped male arousal physiology in considerable detail. Female arousal physiology, by contrast, remained poorly characterized. The investment followed the infrastructure — and the infrastructure had never been built for women.

Dr. Irwin Goldstein, one of the most prominent voices in sexual medicine and a longtime advocate for women's sexual health research, has described the resulting dynamic as a self-reinforcing cycle: limited foundational science produces limited clinical trial designs, which produce limited approved therapies, which produce limited clinical interest, which produces limited funding for foundational science.

The FDA Approval Record

The clearest measure of this disparity sits in the FDA's own approval history. As of 2024, there are more than two dozen FDA-approved pharmacological treatments for male sexual dysfunction. For women, that number sits at two: flibanserin, approved in 2015 for hypoactive sexual desire disorder in premenopausal women, and bremelanotide, approved in 2019 for the same indication.

Neither medication addresses arousal disorder, orgasmic disorder, or the full spectrum of conditions that constitute female sexual dysfunction. Neither has been approved for postmenopausal women, despite the well-documented prevalence of sexual health concerns in that population. The approval record reflects not a lack of patient need but a lack of the clinical trial data required to demonstrate efficacy — data that was never systematically generated.

Researchers working in this space frequently note that the evidentiary standards applied to female sexual health trials have, at times, been applied inconsistently relative to comparable male-focused trials. The 2015 approval of flibanserin was itself preceded by two FDA rejections and a public advocacy campaign that drew attention to the disparity in approved treatments — a campaign that critics argued was partly industry-funded but that also reflected genuine frustration among clinicians and patients.

What Women Are Left With

The practical impact of this research gap lands directly on the examination table.

When a woman presents to her physician with complaints about diminished sexual desire, difficulty achieving orgasm, or persistent arousal problems unrelated to genoiurinary syndrome of menopause, her clinician faces a limited evidence base from which to draw. Off-label prescribing — using medications approved for other conditions to address sexual health concerns — is common, but it is inherently constrained by the absence of robust trial data specifically designed around female sexual outcomes.

Testosterone therapy, for example, has decades of evidence supporting its use in postmenopausal women with hypoactive sexual desire disorder, and international guidelines from organizations including the International Society for the Study of Women's Sexual Health recommend it for this indication. Yet no testosterone product carries FDA approval specifically for women in the United States. Clinicians who prescribe it do so off-label, often navigating insurance denials and patient confusion about why a treatment with substantial evidence behind it lacks formal regulatory status.

The answer, again, comes back to the research gap. Without a dedicated FDA-approved indication, the commercial incentive to fund the large-scale trials that would generate one remains limited.

Researchers Pushing Back

There is, however, meaningful momentum building within the field.

The International Society for the Study of Women's Sexual Health has worked systematically to establish clinical practice recommendations grounded in available evidence, while simultaneously advocating for expanded research investment. Academic sexual medicine programs at institutions including the University of California San Francisco, Boston University, and Loyola University Chicago have produced a generation of researchers specifically focused on female sexual physiology.

Federal funding through the National Institutes of Health has increased modestly for female sexual health research in recent years, though advocates argue that it remains disproportionate to the burden of disease. The NIH's mandate to include women in clinical research — established by the NIH Revitalization Act of 1993 — has improved representation in general health research, but sexual health specifically remains a persistent gap.

Digital health platforms and patient advocacy organizations have also begun generating population-level data on female sexual experience that traditional research structures had never systematically collected. While this data has limitations, it is beginning to fill descriptive gaps that foundational science left open.

Why This Matters for Women Seeking Care Today

For American women navigating sexual health concerns right now, the research gap has an immediate and personal dimension. It means that the menu of evidence-based treatment options is narrower than it should be. It means that clinicians may be less familiar with current guidance than patients deserve. And it means that conversations about female sexual satisfaction are still, in too many clinical settings, treated as peripheral rather than central to women's overall health.

Advocating for oneself within that system requires knowing that the system has failed to do its job — and knowing that the failure is not inevitable. The science of female sexual health is not inherently more complex or more resistant to investigation than male sexual health. It has simply been less funded, less prioritized, and less valued.

Changing that calculus begins with naming the gap clearly, demanding that research institutions and pharmaceutical companies treat female sexual satisfaction as the legitimate medical subject it is, and ensuring that women have access to the most current evidence-based guidance available while the broader infrastructure continues to catch up.